Evidence map›Paper›PMID 30725310›Full record

ArticleAnnals of surgical oncology2019

Treatment of Inguinal Lymph Node Metastases in Patients with Rectal Adenocarcinoma.

J A W Hagemans, J Rothbarth, G H W van Bogerijen, E van Meerten, J J M E Nuyttens, C Verhoef, J W A Burger

Abstract read
In one paragraph

Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J A W HagemansDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. j.hagemans@erasmusmc.nl.ORCID http://orcid.org/0000-0002-2558-4335
J RothbarthDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
G H W van BogerijenDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
E van MeertenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
J J M E NuyttensDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
C VerhoefDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
J W A BurgerDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInguinal lymph node metastases (ILNM) from rectal adenocarcinoma are rare and staged as systemic disease. This study aimed to provide insight into the treatment and prognosis of ILNM from rectal adenocarcinoma.

methodsAll patients with a diagnosis of synchronous or metachronous ILNM from rectal adenocarcinoma between January 2005 and March 2017 were retrospectively reviewed.

resultsThe study identified 27 patients with ILNM (15 with synchronous and 12 with metachronous disease). After discussion by a multidisciplinary tumor board, 19 patients were treated with curative intent, 17 of whom underwent inguinal lymph node dissection. Of the 17 patients, 12 had locally advanced rectal cancer (LARC) with isolated ILNM, 3 had LARC and metastases elsewhere, and 2 had locally recurrent rectal cancer (LRRC). The median overall survival (OS) for all the patients treated with curative intent was 27 months [95% confidence interval (CI) 11.6-42.4 months], with a 5-year OS rate of 34%. The median OS for the patients with LARC and isolated ILNM (n = 12) was 74 months (95% CI 18.0-130.0 months), with a 5-year OS rate of 52%. All the patients with metastases elsewhere (n = 3) or LRRC (n = 2) experienced recurrent systemic disease. Eight patients were treated with palliative intent. The median OS for this group was 13 months (95% CI 1.9-24.1 months), with a 3-year OS rate of 0%.

conclusionClinicians should not consider ILNM as an incurable systemic disease. Patients with primary rectal cancer and solitary ILNM who were eligible for curative surgical treatment had a 5-year survival rate of 52%. The prognosis for patients with additional systemic metastases or LRRC is worse, and the benefit of surgery is unclear.

Indexed as

AdenocarcinomaAdultAgedFemaleFollow-Up StudiesHumansInguinal CanalLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRectal NeoplasmsRetrospective StudiesSurvival Rate

Identifiers

PMID30725310
PMCPMC6399178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.